In draft guidelines issued today, liraglutide 1.2 mg daily has been recommended in combination with metformin or a sulphonylurea for patients intolerant or unsuitable for add-on therapy with metformin, a sulphonylurea, a thiazolidinediones and a dipeptidyl peptidase-4 inhibitor.
As part of triple therapy regimens, liraglutide 1.2mg daily is recommended only when control of blood glucose is inadequate, patients have a BMI over 35 or are unsuitable for insulin therapy.
The institute has recommended liraglutide 1.2mg, but not the 1.8mg dose. It said that available evidence did not suggest any significant additional benefit with the higher dose.
Final NICE guidance on liraglutide is likely to be published in October 2010.